Holen Sie sich die Stockscreener-App
17.36
3.45%
-0.62
Handel nachbörslich:
17.37
0.01
+0.06%
Schlusskurs vom Vortag:
$17.98
Offen:
$17.84
24-Stunden-Volumen:
1.70M
Relative Volume:
0.60
Marktkapitalisierung:
$3.80B
Einnahmen:
$10.68M
Nettoeinkommen (Verlust:
$-272.71M
KGV:
-11.09
EPS:
-1.565
Netto-Cashflow:
$-213.38M
1W Leistung:
-7.36%
1M Leistung:
-8.00%
6M Leistung:
+13.76%
1J Leistung:
+176.87%
1-Tages-Spanne:
$17.27
$17.93
1-Wochen-Bereich:
$16.87
$18.54
52-Wochen-Spanne:
$5.85
$21.27
Relay Therapeutics Inc Stock (RLAY) Company Profile
Firmenname
Relay Therapeutics Inc
Sektor
Branche
Telefon
617-370-8837
Adresse
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
17.36 | 3.80B | 10.68M | -272.71M | -213.38M | -1.565 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-16 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-07-08 | Eingeleitet | JP Morgan | Overweight |
| 2026-01-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-04-17 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-09-10 | Fortgesetzt | Goldman | Buy |
| 2024-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-04-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Eingeleitet | Raymond James | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-09-30 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-02 | Eingeleitet | Stifel | Buy |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-07-21 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-11-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-10 | Eingeleitet | Cowen | Outperform |
| 2020-08-10 | Eingeleitet | Goldman | Buy |
| 2020-08-10 | Eingeleitet | Guggenheim | Buy |
| 2020-08-10 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
Form 4 Relay Therapeutics Inc For: 8 October By Investing.com - Investing.com Canada
Relay Therapeutics CFO Catinazzo sells $329k in shares - Investing.com
Relay Therapeutics CEO Sanjiv Patel sells $872,401 company stock - Investing.com
CEO sells 48,199 shares under a trading plan at Relay Therapeutics (RLAY). - Stock Titan
Under a trading plan, Relay Therapeutics (RLAY) CFO sells 17,511 shares plus 206 more. - Stock Titan
After two share sales, Sanjiv Patel proposes another at Relay Therapeutics (RLAY). - Stock Titan
After two 17,717-share sales, a Relay Therapeutics (RLAY) officer proposes another sale. - Stock Titan
Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option - GlobeNewswire Inc.
Relay Therapeutics (Nasdaq:RLAY)Stock Analysis - simplywall.st
Relay Therapeutics CEO Sanjiv Patel sells 48,199 shares for $912,889.06 - Bitget
Relay Therapeutics (RLAY) Insider Sell: President, R&D Donald Be - GuruFocus
Relay Therapeutics R&D president sells $161,814 in stock By Investing.com - Investing.com South Africa
Relay Therapeutics R&D president sells $161,814 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics R&D president sells $161,814 in stock - Investing.com
Relay Therapeutics R&D president sells $161,814 in stock By Investing.com - Investing.com India
Relay Therapeutics R&D president sells $161,814 in stock By Investing.com - Investing.com Canada
Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics (RLAY) R&D chief sells stock under 10b5-1 plan - Stock Titan
Relay Therapeutics (RLAY) CFO sells about $335K in stock under preset plan - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) CEO sells shares under preset trading plan - Stock Titan
Relay Therapeutics Insider Sold Shares Worth $912,889, According to a Recent SEC Filing - Yahoo Finance
Relay Therapeutics at Wells Fargo conference: pipeline nears key tests By Investing.com - Investing.com Canada
Relay Therapeutics at Wells Fargo conference: pipeline nears key tests By Investing.com - Investing.com UK
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September - news.futunn.com
Relay Therapeutics CFO Sells 17,717 Shares for $350,000 - Yahoo Finance
Relay Therapeutics CFO Sells 17,717 Shares for $350,000 - The Motley Fool
Relay Therapeutics to Participate in Upcoming September Healthcare Conference Fireside Chats - Quiver Quantitative
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September - GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September - finance.yahoo.com
Relay Therapeutics management will join two live online talks this month - Stock Titan
Relay Therapeutics (RLAY) Insider Peter Rahmer Sells 4,508 Shares - GuruFocus
Relay Therapeutics (RLAY) exec sells 4,508 shares under plan - Stock Titan
SoftBank Vision Fund Subsidiary Sells 6 Million Shares of Relay Therapeutics at $19.4 Each - Kalkine Media
Relay Therapeutics director SVF Pauling (Cayman) sells $116.4m By Investing.com - Investing.com Canada
Relay Therapeutics director SVF Pauling (Cayman) sells $116.4m By Investing.com - Investing.com UK
Relay Therapeutics (NASDAQ: RLAY) 10% owner SoftBank sells 6M shares - Stock Titan
Relay Therapeutics director SVF Pauling (Cayman) sells $116.4m - Investing.com
Relay Therapeutics (NASDAQ: RLAY) officer eyes another stock sale after June trade - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) holder plans sale of up to 6M shares - Stock Titan
What is HC Wainwright's Estimate for RLAY FY2027 Earnings? - MarketBeat
RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $29 - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Relay Therapeutics price target to $29 By Investing.com - Investing.com Canada
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE - MarketBeat
Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified? - Yahoo Finance
Relay Therapeutics (RLAY) Stock May Be Fully Valued After A 7x Run - simplywall.st
Timothy G. Youngquist 2020 Irrevocable Trust Boosts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Handelsbanken Fonder AB Buys New Shares in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics Insider Sold Shares Worth $979,886, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics (RLAY) CEO sells 48K shares in plan trade - Stock Titan
Finanzdaten der Relay Therapeutics Inc-Aktie (RLAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Relay Therapeutics Inc-Aktie (RLAY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SANJIV PATEL | Director |
Oct 07 '26 |
Proposed Sale |
18.74 |
96,401 |
1,806,555 |
0 |
| THOMAS CATINAZZO | Officer |
Oct 06 '26 |
Proposed Sale |
19.39 |
93,153 |
1,806,237 |
0 |
| Catinazzo Thomas | Chief Financial Officer |
Oct 06 '26 |
Sale |
18.59 |
17,717 |
329,322 |
105,134 |
| Patel Sanjiv | President and CEO |
Sep 08 '26 |
Sale |
18.94 |
48,199 |
912,889 |
519,500 |
| Catinazzo Thomas | Chief Financial Officer |
Sep 08 '26 |
Sale |
18.94 |
17,717 |
335,560 |
122,851 |
| Bergstrom Donald A | President, R&D |
Sep 08 '26 |
Sale |
18.97 |
8,530 |
161,814 |
399,130 |
| PETER RAHMER | Officer |
Aug 26 '26 |
Proposed Sale |
20.57 |
50,000 |
1,028,500 |
0 |
| Rahmer Peter | See remarks |
Aug 26 '26 |
Sale |
20.03 |
4,508 |
90,295 |
223,657 |
| SVF Pauling (Cayman) Ltd | 10% Owner |
Aug 25 '26 |
Sale |
19.40 |
6,000,000 |
116,400,000 |
21,904,963 |
| SVF Pauling (Cayman) Ltd | Stockholder |
Aug 25 '26 |
Proposed Sale |
20.57 |
6,000,000 |
123,420,000 |
0 |
8.07%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):